Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003236 | 0.87 | CDK2 (0.40) | RAB9ANPC1MAPK1HSD17B10TSHR | |
| SCHEMBL1001887 | 0.82 | MAPK1 (0.41) | RAB9ANPC1MAPK1HSD17B10TSHR | |
| SCHEMBL1003348 | 0.79 | CDK2 (0.44) | RAB9ANPC1MAPK1HSD17B10TSHR | |
| SCHEMBL3511132 | 0.79 | KMT2A (0.39) | RAB9ANPC1MAPK1HSD17B10TSHR | |
| SCHEMBL3507730 | 0.78 | F10 (0.45) | MAPTKDM5BSSTR5 | |
| SCHEMBL12311487 | 0.77 | F10 (0.46) | RAB9AMAPK1HSD17B10TSHRMAPT | |
| SCHEMBL3507693 | 0.76 | L3MBTL1 (0.40) | RAB9ANPC1MAPK1HSD17B10TSHR | |
| SCHEMBL3510539 | 0.74 | F10 (0.45) | — | |
| SCHEMBL3508891 | 0.73 | F10 (0.45) | — | |
| SCHEMBL3506367 | 0.72 | F10 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | F2, VKORC1, HMBS | RAB9A 3266/4885NPC1 1664/4885MAPK1 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.